Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Elan to Pay $203M Off-Label Marketing Fine

By Pharmaceutical Processing | December 16, 2010

WASHINGTON (AP) — Irish pharmaceutical manufacturer Elan
Corporation PLC and its U.S.
subsidiary have agreed to pay more than $203 million for alleged illegal
promotion of the epilepsy drug Zonegran, the Justice Department said Wednesday.

The department said Japanese drug marketer Eisai Inc., which
bought the drug from Elan, will pay $11 million for so-called off-label
marketing of Zonegran.

Elan has agreed to plead guilty to a misdemeanor for
allegedly promoting Zonegran for a wide variety of improper uses, including
mood stabilization, migraine headaches, eating disorders and weight loss.

The Food and Drug administration approved Zonegran as an
anti-epileptic drug, but not for other uses.

Elan will pay a criminal fine of $97 million, will pay
$102.3 million to resolve civil allegations and will forfeit $3.6 million in
assets.

This settlement is part of the government’s emphasis on
combating health care fraud. One of the most powerful tools in that effort is
the False Claims Act, which the Justice Department has used to recover more
than $5 billion since January 2009 in cases involving fraud against federal
health care programs. The Justice Department’s total recoveries in False Claims
Act cases since January 2009 have topped $6 billion.

The settlement resolves a whistle-blower lawsuit filed by a Massachusetts physician.
The law allows citizens with knowledge of fraud to file civil actions on behalf
of the United States
and share in any recovery.

The Justice Department says it has recovered more than $5
billion since January 2009 in cases involving fraud against federal health care
programs.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE